Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 10%

Bulls say

Solventum is expected to thrive under its new structure, as demonstrated by its strong organic growth and increased guidance across all financial metrics. With the separation of the purification and filtration segment and a potential sale or spinoff of the HIS segment, Solventum is on track to maximize shareholder value and unlock the conglomerate discount currently weighing down its stock. Additionally, factors such as improved execution, faster debt paydown, and positive updates on the HIS separation could drive further upside to our already bullish outlook.

Bears say

Solventum is a company that has undergone significant transformation and divestitures in its various business segments, including selling off its smaller purification and filtration segment and announcing plans to separate its healthcare information systems business. In addition, while the company's organic growth in its medsurg segment has been strong, there are concerns about its overreliance on one product (Tegaderm CHG) within the segment and potential timing delays in its ERP implementation. Furthermore, the recent changes to gross margins and operating expenses are expected to impact the company's overall profitability in the near term, with hopes of improvement in the following year.

Solventum Corporation (SOLV) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 10 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.